LAG3 and neoplasm: Regarding the spatial relationship of local immune cells in the tumor tissue of the baseline patients, the following trends were observed: the group of patients with a closer distance between T cells and tumor cells had relatively longer overall survival after CCRT administration, but when the immune checkpoint LAG3 was included in the study, the farther distance from tumors to the nearest LAG3 positive CD4 + or CD8 + T cells resulted in better but statistically insignificant prognosis (Fig. S2D, E).